

DAFTAR PUSTAKA

- Aberer, W., Bircher, A., Romano, A., Blanca, M., Campi, P., *et al.* 2003. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy*, 58(9), 854–863.
- Aceves-Avila, F. J., Benites-Godínez, V. 2008. Drug Allergies May Be More Frequent in Systemic Lupus Erythematosus Than in Rheumatoid Arthritis. *JCR: Journal of Clinical Rheumatology*, 14(5), 261–263.
- Aihara, M. 2011. Pharmacogenetics of cutaneous adverse drug reactions. *The Journal of Dermatology*, 38(3), 246–254.
- Baldo, B., Pham, N. 2013. *Drug Allergy-Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships*. London: Springer-Verlag New York.
- Breen, R. A. M., Miller, R. F., Gorsuch, T., Smith, C. J., Schwenk, A., Holmes, W., Lipman, M. C. I., *et al.* 2006. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. *Thorax*, 61(9), 791–794.
- Barbaud, A. 2009. Skin Testing in Delayed Reactions to Drugs. *Immunology and Allergy Clinics of North America*, 29(3), 517–535.
- Castana, O., Rempelos, G., Anagiotos, G., Apostolopoulou, C., Dimitrouli, A., & Alexakis, D. 2009. Stevens-johnson syndrome: a case report. *Annals of burns and fire disasters*, 22(3), 147-51.
- Carvalho, S. R., Silva, I., Leiria-Pinto, P., Rosado-Pinto, J. 2009. Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case. *Allergol Immunopathol*; 37:336-8.

- Choudhary, S., McLeod, M., Torchia, D., & Romanelli, P. 2013. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. *The Journal of Clinical and Aesthetic Dermatology*, 6(6), 31–37.
- Criado, P., Criado, R., Avancini, J., & Santi, C. 2012. Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. *Anais Brasileiros de Dermatologia*, 87(3), 435-449.
- Davies, P., Barnes, P., Gordon, S. 2008. *Clinical Tuberculosis, Fourth edition*. London: Hodder & Stoughton Ltd.
- Departemen Kesehatan Republik Indonesia. 2014. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta: Depkes RI.
- Forget, E. J., & Menzies, D. (2006). Adverse reactions to first-line antituberculosis drugs. *Expert Opinion on Drug Safety*, 5(2), 231–249.
- Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. 2000. SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. *Journal of Investigative Dermatology*, 115(2), 149–153.
- Garcia-Doval, I., LeCleach, L., Bocquet, H., Otero, X.L., Roujeau, J.C. 2000. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? *Arch. Dermatol.* 136(3), 323–327.
- Graham-Brown, R., Burns, T. 2011. *Lecture Notes: Dermatology, Tenth Edition*. Chichester: Wiley-Blackwell.

Gravendeel, J. M., Asapa, A.S., Becx-Bleumink, M., Vrakking, H.A. 2003.

Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. *Tuberculosis*;83(1-3):183-186.

Gulbay, B.E., Gurkan, O.U., Yildiz, O.A, *et al.* Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. *Respir. Med.* 100(10), 1834–1842 (2006).

Harris, R. Z., Benet, L. Z., & Schwartz, J. B. 1995. Gender Effects in Pharmacokinetics and Pharmacodynamics. *Drugs*, 50(2), 222–239.

Hernandez-Salazar, A., de Leon-Rosales, S. P., Rangel-Frausto, S., Criollo, E., Archer-Dubon, C., & Orozco-Topete, R. 2006. Epidemiology of Adverse Cutaneous Drug Reactions. A Prospective Study in Hospitalized Patients. *Archives of Medical Research*, 37(7), 899–902.

Janardhan, B., Shailendra, D., 2017. Prevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital. *Int J Res Dermatol*; 3(1): 74-78.

Joint Tuberculosis Committee of the British Thoracic Society. 1998. Chemotherapy and management of tuber culosis in the United Kingdom: recommendations 1998. *Thorax* 53(7), 536–548

Joint United Nations Programme on HIV and AIDS. 2018. Data UNAIDS Indonesia. Diambil dari <http://www.unaids.org/en/regionscountries/countries/indonesia>.

- Junior, B.W., & Ferolla, A.C.J. 2005. Acute generalized exanthematous pustulosis (AGEP). Case report. *Revista do Instituto de Medicina Tropical de São Paulo*, 47(3), 171-176.
- Kando, J. C., Yonkers, K. A., & Cole, J. O. 1995. Gender as a Risk Factor for Adverse Events to Medications. *Drugs*, 50(1), 1–6.
- Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C. Y., Creamer, D., *et al.* 2013. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *British Journal of Dermatology*, 169(5), 1071–1080.
- Kastner, M., Wilczynski, N. L., Walker-Dilks, C., McKibbin, K. A., & Haynes, B. 2006. Age-specific search strategies for Medline. *Journal of medical Internet research*, 8(4), e25.
- Kremic, Z., Mijuskovic, Z.P., Kandolf-Sekulovic, L. 2016. Dress Syndrome – A Case Report. *Serbian Journal of Dermatology and Venorology*, 8(2), 95-100.
- Kumar, V., Abbas, A., Aster, J. 2013. *Robbins Basic Pathology*, 9th edition. Philadelphia: Elsevier Saunders.
- Lehloenya, R. J., Todd, G., Badri, M., & Dheda, K. 2011. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. *The International Journal of Tuberculosis and Lung Disease*, 15(12), 1649–1657.

- Lehloenya, R. J., & Dheda, K. 2012. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. *Expert Review of Anti-Infective Therapy*, 10(4), 475–486.
- Lienhardt, C. 2011. Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared with Separate Drugs for Treatment of Pulmonary Tuberculosis. *JAMA*, 305(14).
- Mahajan, V., & Handa, S. 2013. Patch testing in cutaneous adverse drug reactions: Methodology, interpretation, and clinical relevance. *Indian Journal of Dermatology, Venereology, and Leprology*, 79(6), 836.
- Marks, D. J. B., Dheda, K., Dawson, R., Ainslie, G., & Miller, R. F. 2009. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. *International Journal of STD & AIDS*, 20(5), 339–345.
- Marra, F., Marra, C.A., Bruchet, N., Richardson, K., Moadebi, S., Elwood, R.K., et al. 2007. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. *Int. J. Tuberc. Lung Dis*; 11:868–75.
- Mustafa, S. S., Ostrov, D., & Yerly, D. 2018. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management. *Current Allergy and Asthma Reports*, 18(4).
- Nahid, P., Jarlsberg, L. G., Rudoy, I., de Jong, B. C., Unger, A., Kawamura, L. M., Daley, C. L., et al. 2011. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. *BMC Infectious Diseases*, 11(1).
- Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Greenblatt, D. J., et al. 1981. A method for estimating the probability of

adverse drug reactions. *Clinical Pharmacology and Therapeutics*, 30(2), 239–245.

Nayak, S., & Acharjya, B. 2008. Adverse cutaneous drug reaction. *Indian Journal of Dermatology*, 53(1), 2–8.

Ochoa, E.L., Chattopadhyay, A., McNamee, M.G. 1989. Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators. *Cell. Mol. Neurobiol.* 9(2), 141–178.

Ormerod, L. P., & Horsfield, N. (1996). Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment. *Tubercle and Lung Disease*, 77(1), 37–42.

Osman, M. 2003 Therapeutic implications of sex differences in asthma and atopy. *Archives of Disease in Childhood*. 88:587–590.

Pandapotan, R.A., Rengganis, I. 2016. Pendekatan Diagnosis dan Tatalaksana Alergi Obat. *Jurnal Penyakit Dalam Indonesia*. 3(1):45-52.

Patel, T.K., Barvaliya, M.J., Sharma, D., Tripathi, C. 2013. A systematic review of the drug-induced Stevens- Johnson syndrome and toxic epidermal necrolysis in Indian population. *Indian J Dermatol Venereol Leprol.*;79(3):389-98.

Phillips, E., & Mallal, S. 2007. Drug hypersensitivity in HIV. *Current Opinion in Allergy and Clinical Immunology*, 7(4), 324–330.

Pichler, W. J. 2003. Delayed Drug Hypersensitivity Reactions. *Annals of Internal Medicine*, 139(8), 683.

Qayoom, S., Bisati, S., Manzoor, S., Sameem, F., Khan, K. 2015. Adverse Cutaneous drug reactions – a clinico-demographic study in a tertiary care

teaching hospital of the Kashmir Valley, India. *Arch Iran Med.* 18(4):228-33.

Rademaker, M. 2001. Do Women Have More Adverse Drug Reactions? *American Journal of Clinical Dermatology*, 2(6), 349–351.

Rodrigues-Carvalho, S., Silva, I., Leiria-Pinto, P., & Rosado-Pinto, J. 2009. Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case. *Allergologia et Immunopathologia*, 37(6), 336–338.

Shareef, S.M., Krishna, P.S., Tadvi, N.A., Naidu, C.D.M. 2013. Clonazepam induced maculopapular rash: a case report. *International Journal of Basic & Clinical Pharmacology*, 2(5), 647-649.

Sharma, V.K., Sethuraman, G. G. 1996. Adverse cutaneous reactions to drugs: an overview. *J Postgrad Med*, 42, 15-22.

Sharma, V.K., Sethuraman, G., Kumar, B. 2001. Cutaneous adverse drug reactions: clinical pattern & causative agents--a 6-year series from Chandigarh, India. *J Post grad Med.*;47(2):95-9.

Saukkonen, J.J., Cohn, D.L., Jasmer, R.M., et al. 2006. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. *Am. J. Respir. Crit. Care Med.* 174(8), 935–952

Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Le-Louet, H. et al. 2010. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison with Case–Control Analysis. *Clinical Pharmacology & Therapeutics*, 88(1), 60–68.

- Sidoroff, A., Halevy, S., Bavinck, J. N. B., Vaillant, L., & Roujeau, J.-C. 2001. Acute generalized exanthematous pustulosis (AGEP) - A clinical reaction pattern. *Journal of Cutaneous Pathology*, 28(3), 113–119.
- Sophiati, M. 2017. Analisis Retrospektif Pada Pasien *Adverse Cutaneous Drug Reactions* (ACDR) Dengan Reaksi Hipersensitivitas Tipe IV Berdasarkan Agen Kausatif Dan Faktor Resiko di RSUP dr. Sardjito Yogyakarta Periode 2011-2015. Yogyakarta: Fakultas Kedokteran Universitas Gadjah Mada.
- Sousa-Pinto, B., Araújo, L., Freitas, A., Correia, O., & Delgado, L. 2018. Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. *Clinical and Translational Allergy*, 8(1).
- Soutor, C., Hordinsky, M. 2013. *Clinical Dermatology, 1st Edition*. New York City: McGraw-Hill Education
- Szatkowski, J., & Schwartz, R. A. 2015. Acute generalized exanthematous pustulosis (AGEP): A review and update. *Journal of the American Academy of Dermatology*, 73(5), 843–848.
- Tajmir-Riahi, A., Wörl, P., Harrer, T., Schliep, S., Schuler, G., & Simon, M. 2017. Life-Threatening Atypical Case of Acute Generalized Exanthematous Pustulosis. *International Archives of Allergy and Immunology*, 174(2), 108–111.
- Tan, W.C., Ong, C.K., Kang, S.C., Razak, M.A. 2007. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. *Med. J. Malaysia* 62(2), 143–146

- Thong, B. Y.-H., & Tan, T.-C. 2011. Epidemiology and risk factors for drug allergy. *British Journal of Clinical Pharmacology*, 71(5), 684–700.
- Verma, R., Vasudevan, B., & Pragasam, V. 2013. Severe cutaneous adverse drug reactions. *Medical Journal Armed Forces India*, 69(4).
- World Health Organization. 2017. Global tuberculosis report 2017. Diambil dari http://www.who.int/tb/publications/global_report/en/
- Wrighton, S.A., Stevens, J.C. 1995. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol* 1992; 22: 1-21 Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. *Drugs*; 50: 222-39
- Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. 2003. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, 167(11), 1472–1477.
- Yunihastuti, E., Widhani, A., & Karjadi, T. H. 2014. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. *Asia Pacific Allergy*, 4(1), 54.